When the low may still be high: the heavy burden of residual psoriasis in difficult‐to‐treat areas despite a low DLQI score among patients under biologics or apremilast: a 5‐year, prospective, case‐control study
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.17703
Abstract: Patients with psoriasis in difficult-to-treat areas experience substantial impairment in their welfare.1 Despite the remarkable efficacy of biologics, some patients may still suffer from residual disease in those sites affecting their everyday life.2,3 Therefore, we… read more here.
Keywords: difficult treat; treat areas; may still; dermatology ... See more keywords